SCHEMBL4095229

SCHEMBL4095229

CC(=O)N1CCN(c2nc(-c3ccccc3Cl)nc3cccc(F)c23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.48
ABCB1 P08183 1/20 0.48
MAPT P10636 4/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GBA1 P04062 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CNR1 P21554 2/20 0.43
HIF1A Q16665 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
PKM P14618 1/20 0.42
CASP1 P29466 1/20 0.42
KLK7 P49862 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095765 0.92 MAPT (0.53) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4090729 0.91 ABCB1 (0.52) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4099593 0.91 HIF1A (0.51) CNR2MAPTMEN1KMT2AGBA1
SCHEMBL4085062 0.88 CNR2 (0.49) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4094778 0.87 KMT2A (0.50) ABCB1MAPTMEN1KMT2ACYP1A2
SCHEMBL4095459 0.87 CNR2 (0.48) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4091807 0.86 MAPT (0.48) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4084544 0.84 ABCB1 (0.67) ABCB1MAPTMEN1KMT2ACYP1A2
SCHEMBL4097324 0.84 ABCB1 (0.70) CNR2ABCB1MAPTMEN1KMT2A
SCHEMBL4085201 0.80 ABCB1 (0.53) CNR2ABCB1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 CNR2 1/4885ABCB1 2120/4885MAPT 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.